Cardiovascular Risk Detection Using SNP Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for estimating cardiovascular risk are inadequate, as they fail to accurately predict who is at higher risk of developing cardiovascular disease, leading to missed opportunities for preventive measures and ineffective treatment strategies.
Innovation Solution
The use of specific single nucleotide polymorphism (SNP) markers at positions 27 within nucleic acid sequences to determine an individual's risk of adverse cardiovascular events or response to therapy, combining these genetic markers with conventional risk factors to improve predictive accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional risk factor assessment methods are used, then the estimation process is simple, but the predictive accuracy of cardiovascular risk is insufficient
Solution Approach 1:
The patent changes the parameter of risk assessment by incorporating genetic polymorphism data (specifically at position 27 of certain nucleic acid sequences) alongside conventional risk factors. This addition of genetic parameters improves predictive accuracy by identifying individuals with increased cardiovascular risk who would be missed by conventional methods alone, while the complexity increase is managed through standardized genotyping protocols.
2Measurement precision
If genetic markers are incorporated to improve risk prediction, then the predictive accuracy increases, but the cost and complexity of testing increases
Solution Approach 1:
The patent extracts and focuses on a specific, limited set of genetic markers (polymorphisms at position 27 of certain nucleic acid sequences) rather than analyzing the entire genome. This targeted extraction approach improves risk stratification precision by concentrating on the most relevant genetic variants while keeping testing complexity and cost manageable through focused genotyping rather than comprehensive genomic analysis.
3Reliability
If more tests are used for precise risk stratification, then the identification of high-risk individuals improves, but the time and resources required increase
Solution Approach 1:
The patent performs preliminary genetic testing to identify individuals with specific polymorphisms at position 27 before initiating comprehensive cardiovascular risk management. This preliminary action allows for early identification of high-risk individuals, enabling preventive measures to be taken before adverse cardiovascular events occur, thereby improving reliability of risk identification while minimizing time loss through upfront genotyping.
Data Source
AI summary
The invention relates to a method for determining the risk of suffering a cardiovascular disease based on the presence of different polymorphisms as well as to kits for practicing the above method. The invention also relates to a method for determining the risk of suffering a cardiovascular disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for CVD as well as computer-implemented means for carrying out said method.